Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination.

Jansen JM, Gerlach T, Elbahesh H, Rimmelzwaan GF, Saletti G.

J Clin Virol. 2019 Oct;119:44-52. doi: 10.1016/j.jcv.2019.08.009. Epub 2019 Aug 24. Review.

PMID:
31491709
2.

Response Modifiers: Tweaking the Immune Response Against Influenza A Virus.

Elbahesh H, Gerlach T, Saletti G, Rimmelzwaan GF.

Front Immunol. 2019 Apr 12;10:809. doi: 10.3389/fimmu.2019.00809. eCollection 2019. Review.

3.

Recombinant influenza A viruses as vaccine vectors.

Gerlach T, Elbahesh H, Saletti G, Rimmelzwaan GF.

Expert Rev Vaccines. 2019 Apr;18(4):379-392. doi: 10.1080/14760584.2019.1582338. Epub 2019 Mar 4.

PMID:
30777467
4.

Broadly protective influenza vaccines: design and production platforms.

Elbahesh H, Saletti G, Gerlach T, Rimmelzwaan GF.

Curr Opin Virol. 2019 Feb;34:1-9. doi: 10.1016/j.coviro.2018.11.005. Epub 2018 Nov 27. Review.

PMID:
30497050
5.

Influenza vaccines: 'tailor-made' or 'one fits all'.

Saletti G, Gerlach T, Rimmelzwaan GF.

Curr Opin Immunol. 2018 Aug;53:102-110. doi: 10.1016/j.coi.2018.04.015. Epub 2018 May 4. Review.

PMID:
29734023
6.

Circulating Gut-Homing (α4β7+) Plasmablast Responses against Shigella Surface Protein Antigens among Hospitalized Patients with Diarrhea.

Sinha A, Dey A, Saletti G, Samanta P, Chakraborty PS, Bhattacharya MK, Ghosh S, Ramamurthy T, Kim JO, Yang JS, Kim DW, Czerkinsky C, Nandy RK.

Clin Vaccine Immunol. 2016 Jul 5;23(7):610-7. doi: 10.1128/CVI.00205-16. Print 2016 Jul.

7.

Human Circulating Antibody-Producing B Cell as a Predictive Measure of Mucosal Immunity to Poliovirus.

Dey A, Molodecky NA, Verma H, Sharma P, Yang JS, Saletti G, Ahmad M, Bahl SK, Wierzba TF, Nandy RK, Deshpande JM, Sutter RW, Czerkinsky C.

PLoS One. 2016 Jan 5;11(1):e0146010. doi: 10.1371/journal.pone.0146010. eCollection 2016.

8.

Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood.

Saletti G, Çuburu N, Yang JS, Dey A, Czerkinsky C.

Nat Protoc. 2013 Jun;8(6):1073-87. doi: 10.1038/nprot.2013.058. Epub 2013 May 9.

PMID:
23660756
9.

Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity.

Uematsu Y, Vajdy M, Lian Y, Perri S, Greer CE, Legg HS, Galli G, Saletti G, Otten GR, Rappuoli R, Barnett SW, Polo JM.

Clin Vaccine Immunol. 2012 Jul;19(7):991-8. doi: 10.1128/CVI.00031-12. Epub 2012 May 23.

10.

A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteers.

Jang HC, Kim CJ, Kim KH, Lee KH, Byun YH, Seong BL, Saletti G, Czerkinsky C, Park WB, Park SW, Kim HB, Kim NJ, Oh MD.

Vaccine. 2010 Aug 16;28(36):5845-9. doi: 10.1016/j.vaccine.2010.06.063. Epub 2010 Jun 30.

PMID:
20600480
11.

Coligation of the hepatitis C virus receptor CD81 with CD28 primes naive T lymphocytes to acquire type 2 effector function.

Serra A, Nuti S, Tavarini S, Sammicheli C, Rosa D, Saletti G, Soldaini E, Abrignani S, Wack A.

J Immunol. 2008 Jul 1;181(1):174-85.

12.

Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level.

Stadler K, Ha HR, Ciminale V, Spirli C, Saletti G, Schiavon M, Bruttomesso D, Bigler L, Follath F, Pettenazzo A, Baritussio A.

Am J Respir Cell Mol Biol. 2008 Aug;39(2):142-9. doi: 10.1165/rcmb.2007-0217OC. Epub 2008 Feb 28.

PMID:
18314540
13.

Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders.

Rosa D, Saletti G, De Gregorio E, Zorat F, Comar C, D'Oro U, Nuti S, Houghton M, Barnaba V, Pozzato G, Abrignani S.

Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18544-9. Epub 2005 Dec 9.

14.

Genomic approach for analysis of surface proteins in Chlamydia pneumoniae.

Montigiani S, Falugi F, Scarselli M, Finco O, Petracca R, Galli G, Mariani M, Manetti R, Agnusdei M, Cevenini R, Donati M, Nogarotto R, Norais N, Garaguso I, Nuti S, Saletti G, Rosa D, Ratti G, Grandi G.

Infect Immun. 2002 Jan;70(1):368-79.

15.

Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates.

Heile JM, Fong YL, Rosa D, Berger K, Saletti G, Campagnoli S, Bensi G, Capo S, Coates S, Crawford K, Dong C, Wininger M, Baker G, Cousens L, Chien D, Ng P, Archangel P, Grandi G, Houghton M, Abrignani S.

J Virol. 2000 Aug;74(15):6885-92.

16.

Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for Valpha24+ T cells and rapid elimination of effector cells by apoptosis.

Nuti S, Rosa D, Valiante NM, Saletti G, Caratozzolo M, Dellabona P, Barnaba V, Abrignani S.

Eur J Immunol. 1998 Nov;28(11):3448-55.

17.

Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant.

Di Tommaso A, Saletti G, Pizza M, Rappuoli R, Dougan G, Abrignani S, Douce G, De Magistris MT.

Infect Immun. 1996 Mar;64(3):974-9.

18.

[Interaction of the 3rd component of complement (C3) with the surface of LS murine fibroblasts].

Melandri P, Saletti G, Benassi G.

Boll Soc Ital Biol Sper. 1983 Jan 31;59(2):192-8. Italian.

PMID:
6860494

Supplemental Content

Loading ...
Support Center